NCT06272747View on ClinicalTrials.gov

Study of XH-S003 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

July 30, 2024

Study Completion Date

November 30, 2024

Conditions
Healthy Adults
Interventions
DRUG

XH-S003

IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

DRUG

Placebo

Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

Trial Locations (1)

Unknown

Beijing Friendship Hospital,Capital Medical University, Beijing

All Listed Sponsors
lead

S-INFINITY Pharmaceuticals Co., Ltd

INDUSTRY